Prostate cancer, BRCA-mutated

From - A Hematology Oncology Wiki
Jump to navigation Jump to search
Page editor Section editor
Laura S. Graham, MD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA

Social-twitter-icon.png LauraGrahamMD
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA

Social-twitter-icon.png arkhaki
1 regimens on this page
1 variants on this page

Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.

Metastatic castration-resistant

Rucaparib monotherapy

back to top


Study Years of enrollment Evidence
(TRITON2) 2017-NR Phase II (RT)

Note: this study is the basis of FDA approval; however, no dosing details are provided on and there are no published manuscripts to date.

Targeted therapy


  1. TRITON2: NCT02952534